Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents

Current Cancer Drug Targets

Volumn 4, Issue 2, 2004, Pages 165-182

  Gupta, V ^a   Harkin, D P ^b   Kawakubo, H ^a   Maheswaran, S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; ENDOGLIN; FOLLISTATIN; INHIBIN; MUELLERIAN INHIBITING FACTOR; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; MALIGNANT TRANSFORMATION; MAMMARY GLAND; OLIGOMERIZATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ACTIVINS; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MORPHOGENETIC PROTEINS; BREAST NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; INHIBINS; SIGNAL TRANSDUCTION; TESTICULAR HORMONES; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 1542619346     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043481542     Document Type: Review

References (155)

1. Marshall, W. A.; Tanner, J. M. Variations in Pattern of Pubertal Changes in Girls. Arch. Dis. Child 1969, 44, 291-303.
2. Nandi, S. Endocrine Control of Mammary Gland Development and Function in the C3H/He Crg1 Mouse. J. Natl. Cancer 1958, 21, 1039-1063.
3. Angeli, A.; Bradlow, H. L.; Dogliotti, L., Eds. Endocrinology of the Breast: Basic and Clinical Aspects; The New York Academy of Sciences, 1986.
4. Li, C.; Guo, B.; Wilson, P. B.; Stewart, A.; Byrne, G.; Bundred, N.; Kumar, S. Plasma Levels of Soluble CD105 Correlate with Metastasis in Patients with Breast Cancer. Int. J. Cancer 2000, 89, 122-126.
5. Barcellos-Hoff, M. H.; Ewan, K. B. Transforming Growth Factor-Beta and Breast Cancer: Mammary Gland Development. Breast Cancer Res. 2000, 2, 92-99.
6. Donovan, J.; lingerland, J. S. Transforming Growth Factor-Beta and Breast Cancer: Cell Cycle Arrest by Transforming Growth Factor-Beta and Its Disruption in Cancer. Breast Cancer Res. 2000, 2, 116-124.
7. Dumont, N.; Arteaga, C. L. Transforming Growth Factor-Beta and Breast Cancer: Tumor Promoting Effects of Transforming Growth Factor-Beta. Breast Cancer Res. 2000, 2, 125-132.
8. Kretzschmar, M. Transforming Growth Factor-Beta and Breast Cancer: Transforming Growth Factor-Beta/SMAD Signaling Defects and Cancer. Breast Cancer Res. 2000, 2, 107-115.
9. Pollard, J. W. Tumour-Stromal Interactions. Transforming Growth Factor-Beta Isoforms and Hepatocyte Growth Factor/Scatter Factor in Mammary Gland Ductal Morphogenesis. Breast Cancer Res. 2001, 3, 230-237.
10. Teicher, B. A. Malignant Cells, Directors of the Malignant Process: Role of Transforming Growth Factor-Beta. Cancer Metastasis Rev. 2001, 20, 133-143.
11. Wakefield, L. M.; Piek, E.; Bottinger, E. P. TGF-Beta Signaling in Mammary Gland Development and Tumorigenesis. J. Mammary Gland Biol. Neoplasia 2001, 6, 67-82.
12. Walker, R. A. Transforming Growth Factor Beta and Its Receptors: Their Role in Breast Cancer. Histopathology 2000, 36, 178-180.
13. Wakefield, L. M.; Yang, Y. A.; Dukhanina, O. Transforming Growth Factor-Beta and Breast Cancer: Lessons Learned from Genetically Altered Mouse Models. Breast Cancer Res. 2000, 2, 100-106.
14. Slingerland, J. Transforming Growth Factor-Beta and Breast Cancer: Introduction. Breast Cancer Res. 2000, 2, 91.
15. Harris, J. R.; Lippman, M. E.; Morrow, M.; Osborne, C. K., Eds. Diseases of the Breast; Lippincott, Williams and Wilkins 2000.
16. Sakuma, R.; Ohnishi, Yi. Y.; Meno, C.; Fujii, H.; Juan, H.; Takeuchi, J. ; Ogura, T.; Li, E.; Miyazono, K.; Hamada, H. Inhibition of Nodal Signalling by Lefty Mediated through Interaction with Common Receptors and Efficient Diffusion. Genes Cells 2002, 7, 401-412.
17. Ying, S. Y. Inhibins, Activins and Follistatins. J. Steroid Biochem. 1989, 33, 705-713.
18. Yamaguchi, Y.; Mann, D. M.; Ruoslahti, E. Negative Regulation of Transforming Growth Factor-Beta by the Proteoglycan Decorin. Nature 1990, 346, 281-284.
19. Schneyer, A.; Tortoriello, D.; Sidis, Y.; Keutmann, H.; Matsuzaki, T.; Holmes, W. Follistatin-Related Protein (FSRP): A New Member of the Follistatin Gene Family. Mol. Cell. Endocrinol. 2001, 180, 33-38.
20. Massague, J. TGF-Beta Signal Transduction. Annu Rev Biochem. 1998, 67, 753-791.
21. Balemans, W.; Van Hul, W. Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators. Dev. Biol. 2002, 250, 231-250.
22. Chang, H.; Brown, C. W.; Matzuk, M. M. Genetic Analysis of the Mammalian Transforming Growth Factor-Beta Superfamily. Endocr Rev. 2002, 23, 787-823.
23. Attisano, L.; Wrana, J. L. Signal Transduction by the TGF-Beta Superfamily. Science 2002, 296, 1646-1647.
24. Sovak, M. A.; Arsura, M.; Zanieski, G.; Kavanagh, K. T.; Sonenshein, G. E. The Inhibitory Effects of Transforming Growth Factor Betal on Breast Cancer Cell Proliferation are Mediated through Regulation of Aberrant Nuclear Factor-Kappab/Rel Expression. Cell Growth Differ. 1999, 10, 537-544.
25. Segev, D. L.; Ha, T. U.; Tran, T. T.; Kenneally, M.; Harkin, P.; Jung, M.; MacLaughlin, D. T.; Donahoe, P. K.; Maheswaran, S. Mullerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFkappa B-Mediated Pathway. J. Biol. Chem. 2000, 275, 28371-28379.
26. de Kretser, D. M.; Meinhardt, A.; Meehan, T.; Phillips, D. J.; O'Bryan, M. K.; Loveland, K. A. The Roles of Inhibin and Related Peptides in Gonadal Function. Mol. Cell. Endocrinol. 2000, 161, 43-46.
27. Chen, Y. G.; Lui, H. M.; Lin, S. L.; Lee, J. M.; Ying, S. Y. Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin. Exp. Biol. Med. (Maywood) 2002, 227, 75-87.
28. Risbridger, G. P.; Schmitt, J. F.; Robertson, D. M. Activins and Inhibins in Endocrine and Other Tumors. Endocr. Rev. 2001, 22, 836-858.
29. Ying, S. Y.; Zhang, Z.; Furst, B.; Batres, Y.; Huang, G.; Li, G. Activins and Activin Receptors in Cell Growth. Proc. Soc. Exp. Biol. Med. 1997, 214, 114-122.
30. Robinson, G. W.; Hennighausen, L. Inhibins and Activins Regulate Mammary Epithelial Cell Differentiation through Mesenchymal-Epithelial Interactions. Development 1997, 124, 2701-2708.
31. Di Loreto, C.; Reis, F. M.; Cataldi, P.; Zuiani, C.; Luisi, S.; Beltrami, C. A.; Petraglia, F. Human Mammary Gland and Breast Carcinoma Contain Immunoreactive Inhibin/Activin Subunits: Evidence for a Secretion into Cystic Fluid. Eur. J. Endocrinol. 1999, 141, 190-194.
32. Liu, Q. Y.; Niranjan, B.; Gomes, P.; Gomm, J. J.; Davies, D. R.; Coombes, C.; Buluwela, L. Inhibitory Effects of Activin on the Growth and Morpholgenesis of Primary and Transformed Mammary Epithelial Cells. Cancer Res. 1996, 56, 1155-1163.
33. Ying, S. Y.; Zhang, Z. Expression and Localization of Inhibin/Activin Subunits and Activin Receptors in MCF-7 Cells, A Human Breast Cancer Cell Line. Breast Cancer Res. Treat. 1996, 37, 151-160.
34. Sheth, A. R.; Chinoy, R. F.; Garde, S. V.; Panchal, C. J.; Sheth, N. A. Immunoperoxidase Localization and Denovo Biosynthesis of a 10.5-Kda Inhibin in Benign and Malignant Conditions of Human Breast. Cancer Lett. 1993, 72, 127-134.
35. Reinholz, M. M.; Iturria, S. J.; Ingle, J. N.; Roche, P. C. Differential Gene Expression of TGF-Beta Family Members and Osteopontin in Breast Tumor Tissue: Analysis by Real-Time Quantitative PCR. Breast Cancer Res. Treat. 2002, 74, 255-269.
36. Reis, F. M.; Cobellis, L. L.; Tameirao, C.; Anania, G.; Luisi, S.; Silva, I. S.; Gioffre, W.; Di Blasio, A. M.; Petraglia, F. Serum and Tissue Expression of Activin A in Postmenopausal Women with Breast Cancer. J. Clin. Endocrinol. Metab. 2002, 87, 2277-2282.
37. Kalkhoven, E.; Roelen, B. A.; de Winter, J. P.; Mummery, C. L.; Van Den Eijnden-Van Raaij, A. J.; Van Der Saag, P. T.; Van Der Burg, B. Resistance to Transforming Growth Factor Beta and Activin Due to Reduced Receptor Expression in Human Breast Tumor Cell Lines. Cell Growth Differ. 1995, 6, 1151-1161.
38. Petraglia, F.; Florio, P.; Luisi, S.; Gallo, R.; Gadducci, A.; Vigano, P.; Di Blasio, A. M.; Genazzani, A. R.; Vale, W. Expression and Secretion of Inhibin and Activin in Normal and Neoplastic Uterine Tissues. High Levels of Serum Activin A in Women with Endometrial and Cervical Carcinoma. J. Clin. Endocrinol. Metab. 1998, 83, 1194-1200.
39. Kleeff, J.; Ishiwata, T.; Friess, H.; Buchler, M. W.; Korc, M. Concomitant Over-Expression of Activin/Inhibin Beta Subunits and their Receptors in Human Pancreatic Cancer. Int. J. Cancer 1998, 77, 860-868.
40. Wildi, S.; Kleeff, J.; Maruyama, H.; Maurer, C. A.; Buchler, M. W.; Korc, M. Overexpression of Activin A in Stage IV Colorectal Cancer. Gut 2001, 49, 409-417.
41. Sakai, R.; Eto, Y. Involvement of Activin in the Regulation of Bone Metabolism. Mol. Cell. Endocrinol. 2001, 180, 183-188.
42. Vanttinen, T.; Kuulasmaa, T.; Liu, J.; Voutilainen, R. Expression of Activin/Inhibin Receptor and Binding Protein Genes and Regulation of Activin/Inhibin Peptide Secretion in Human Adrenocortical Cells. J. Clin. Endocrinol. Metab. 2002, 87, 4257-4263.
43. Russo, I. H.; Russo, J. Hormonal Approach to Breast Cancer Prevention. J. Cell Biochem. Suppl. 2000, 34, 1-6.
44. Ho, T. Y.; Russo, J.; Russo, I. H. Polypeptide Pattern of Human Breast Epithelial Cells Following Human Chorionic Gonadotropin (Hcg) Treatment. Electrophoresis 1994, 15, 746-750.
45. Charpentier, A. H.; Bednarek, A. K.; Daniel, R. L.; Hawkins, K. A.; Laflin, K. J.; Gaddis, S.; MacLeod, M. C.; Aldaz, C. M. Effects of Estrogen on Global Gene Expression: Identification of Novel Targets of Estrogen Action. Cancer Res. 2000, 60, 5977-5983.
46. Mathews, L. S.; Vale, W. W. Expression Cloning of an Activin Receptor, A Predicted Transmembrane Serine Kinase. Cell 1991, 65, 973-982.
47. Martens, J. W.; Winter, J. P.; Timmerman, de M. A.; McLuskey, A.; van Schaik, R. H.; Themmen, A. P.; de Jong, F. H. Inhibin Interferes with Activin Signaling at the Level of the Activin Receptor Complex in Chinese Hamster Ovary Cells. Endocrinology 1997, 138, 2928-2936.
48. Sankar, S.; Mahooti-Brooks, N.; Centrella, M.; McCarthy, T. L.; Madri, J. A. Expression of Transforming Growth Factor Type III Receptor in Vascular Endothelial Cells Increases their Responsiveness to Transforming Growth Factor Beta 2. J. Biol. Chem. 1995, 270, 13567-13572.
49. Lopez-Casillas, F.; Wrana, J. L.; Massague, J. Betaglycan Presents Ligand to the TGF Beta Signaling Receptor. Cell 1993, 73, 1435-1444.
50. Gray, P. C.; Bilezikjian, L. M.; Vale, W. Antagonism of Activin by Inhibin and Inhibin Receptors: A Functional Role for Betaglycan. Mol. Cell. Endocrinol. 2002, 188, 254-260.
51. Lewis, K. A.; Gray, P. C.; Blount, A. L.; MacConell, L. A.; Wiater, E.; Bilezikjian, L. M.; Vale, W. Betaglycan Binds Inhibin and Can Mediate Functional Antagonism of Activin Signalling. Nature 2000, 404, 411-414.
52. Matzuk, M. M. In Search of Binding-Identification of Inhibin Receptors. Endocrinology 2000, 141, 2281-2284.
53. Chong, H.; Pangas, S. A.; Bernard, D. J.; Wang, E.; Gitch, J.; Chen, W.; Draper, L. B.; Cox, E. T.; Woodruff, T. K. Structure and Expression of a Membrane Component of the Inhibin Receptor System. Endocrinology 2000, 141, 2600-2607.
54. Xu, J.; McKeehan, K.; Matsuzaki, K.; McKeehan, W. L. Inhibin Antagonizes Inhibition of Liver Cell Growth by Activin by a Dominant-Negative Mechanism. J. Biol. Chem. 1995, 270, 6308-6313.
55. Chapman, S. C.; Woodruff, T. K. Modulation of Activin Signal Transduction by Inhibin B and Inhibin-Binding Protein (lnhbp). Mol Endocrinol. 2001, 15, 668-679.
56. Yoshikawa, S. I.; Aota, S.; Shirayoshi, Y.; Okazaki, K. The Actr-1 Activin Receptor Protein Is Expressed in Notochord, Lens Placode and Pituitary Primordium Cells in the Mouse Embryo. Mech. Dev. 2000, 91, 439-444.
57. Goggins, M.; Shekher, M.; Turnacioglu, K. C.; Yeo, J.; Hruban, R. H.; Kern, S. E. Genetic Alterations of the Transforming Growth Factor Beta Receptor Genes in Pancreatic and Biliary Adenocarcinomas. Cancer Res. 1998, 58, 5329-5332.
58. Bianco, C.; Adkins, H. B.; Wechselberger, C.; Seno, M.; Normanno, N.; De Luca, A.; Sun, Y.; Khan, N.; Kenney, N.; Ebert, A.; Williams, K. P.; Sanicola, M.; Salomon, D. S. Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells. Mol. Cell. Biol. 2002, 22, 2586-2597.
59. Mori, Y.; Yin, J.; Rashid, A.; Leggett, B. A.; Young, J.; Simms, L.; Kuehl, P. M.; Langenberg, P.; Meltzer, S. J.; Stine, O. C. Instabilotyping: Comprehensive Identification of Frameshift Mutations Caused by Coding Region Microsatellite Instability. Cancer Res. 2001, 61, 6046-6049.
60. Su, G. H.; Bansal, R.; Murphy, K. M.; Montgomery, E.; Yeo, C. J.; Hruban, R. H.; Kern, S. E. ACVR1B (ALK4, Activin Receptor Type 1B) Gene Mutations in Pancreatic Carcinoma. Proc. Natl. Acad. Sci. USA 2001, 98, 3254-3257.
61. Alexander, J. M.; Bikkal, H. A.; Zervas, N. T.; Laws, E. R. Jr.; Klibanski, A. Tumor-Specific Expression and Alternate Splicing of Messenger Ribonucleic Acid Encoding Activin/Transforming Growth Factor-Beta Receptors in Human Pituitary Adenomas. J. Clin. Endocrinol. Metab. 1996, 81, 783-790.
62. Danila, D. C.; Zhang, X.; Zhou, Y.; Haidar, J. N.; Klibanski, A. Overexpression of Wild-Type Activin Receptor Alk4-I Restores Activin Antiproliferative Effects in Human Pituitary Tumor Cells. J. Clin. Endocrinol. Metab. 2002, 87, 4741-4746.
63. van Schaik, R. H.; Wierikx, C. D.; Timmerman, M. A.; Oomen, M. H.; van Weerden, W. M.; van der Kwast, T. H.; van Steenbrugge, G. J.; de Jong, F. H. Variations in Activin Receptor, Inhibin/Activin Subunit and Follistatin Mrnas in Human Prostate Tumour Tissues. Br. J. Cancer 2000, 82, 112-117.
64. Cocolakis, E.; Lemay, S.; Ali, S.; Lebrun, J. J. The P38 MAPK Pathway is Required for Cell Growth Inhibition of Human Breast Cancer Cells in Response to Activin. J. Biol. Chem. 2001, 276, 18430-18436.
65. Schier, A. F.; Shen, M. M. Nodal Signalling in Vertebrate Development. Nature 2000, 403, 385-389.
66. Salomon, D. S.; Bianco, C.; De Santis, M. Cripto: A Novel Epidermal Growth Factor (EGF)-Related Peptide in Mammary Gland Development and Neoplasia. Bioessays 1999, 21, 61-70.
67. Riese, D. J. 2nd,; Stern, D. F. Specificity within the EGF Family/Erbb Receptor Family Signaling Network. Bioessays 1998, 20, 41-48.
68. Brandt, R.; Normanno, N.; Gullick, W. J.; Lin, J. H.; Harkins, R.; Schneider, D.; Jones, B. W.; Ciardiello, F.; Persico, M. G.; Armenante, F. Identification and Biological Characterization of an Epidermal Growth Factor-Related Protein: Cripto-1. J. Biol. Chem. 1994, 269, 17320-17328.
69. Reissmann, E.; Jornvall, H.; Blokzijl, A.; Andersson, O.; Chang, C.; Minchiotti, G.; Persico, M. G.; Ibanez, C. F.; Brivanlou, A. H. The Orphan Receptor ALK7 and the Activin Receptor ALK4 Mediate Signaling by Nodal Proteins during Vertebrate Development. Genes Dev. 2001, 15, 2010-2022.
70. Song, J.; Oh, S. P.; Schrewe, H.; Nomura, M.; Lei, H.; Okano, M.; Gridley, T.; Li, E. The Type II Activin Receptors Are Essential for Egg Cylinder Growth, Gastrulation, and Rostral Head Development in Mice. Dev. Biol. 1999, 213, 157-169.
71. Gu, Z.; Nomura, M.; Simpson, B. B.; Lei, H.; Feijen, A.; van den Eijnden-van Raaij, J.; Donahoe, P. K.; Li, E. The Type 1 Activin Receptor Actrib Is Required for Egg Cylinder Organization and Gastrulation in the Mouse. Genes Dev. 1998, 12, 844-857.
72. Niemeyer, C. C.; Persico, M. G.; Adamson, E. D. Cripto: Roles in Mammary Cell Growth, Survival, Differentiation and Transformation. Cell Death Differ. 1998, 5, 440-449.
73. Herrington, E. E.; Ram, T. G.; Salomon, D. S.; Johnson, G. R.; Gullick, W. J.; Kenney, N.; Hosick, H. L. Expression of Epidermal Growth Factor-Related Proteins in the Aged Adult Mouse Mammary Gland and their Relationship to Tumorigenesis. J. Cell Physiol. 1997, 170, 47-56.
74. Saloman, D. S.; Bianco, C.; Ebert, A. D. N.; Khan, I.; De Santis, M.; Normanno, N.; Wechselberger, C.; Seno, M.; Williams, K.; Sanicola, M.; Foley, S.; Gullick, W. J.; Persico, G. The EGF-CFC Family: Novel Epidermal Growth Factor-Related Proteins in Development and Cancer. Endocr. Relat. Cancer 2000, 7, 199-226.
75. Arnold, S. F.; Tims, E.; McGrath, B. E. Identification of Bone Morphogenetic Proteins and their Receptors in Human Breast Cancer Cell Lines: Importance of Bmp2. Cytokine 1999, 11, 1031-1037.
76. Bunyaratavej, P.; Hullinger, T. G.; Somerman, M. J. Bone Morphogenetic Proteins Secreted by Breast Cancer Cells Upregulate Bone Sialoprotein Expression in Preosteoblast Cells. Exp. Cell Res. 2000, 260, 324-333.
77. Clement, J. H.; Marr N.; Meissner, A.; Schwalbe, M.; Sebald, W.; Kliche, K. O.; Hoffken, K.; Wolfl, S. Bone Morphogenetic Protein 2 (BMP-2) Induces Sequential Changes of Id Gene Expression in the Breast Cancer Cell Line MCF-7. J Cancer Res. Clin. Oncol. 2000, 126, 271-279.
78. Clement, J. H.; Sanger, J.; Hoffken, K. Expression of Bone Morphogenetic Protein 6 in Normal Mammary Tissue and Breast Cancer Cell Lines and Its Regulation by Epidermal Growth Factor. Int. J. Cancer 1999, 80, 250-256.
79. Phippard, D. J.; Weber-Hall, S. J.; Sharpe, P. T.; Naylor, M. S.; Jayatalake, H.; Maas, R.; Woo, I.; Roberts-Clark, D.; Francis-West, P. H.; Liu, Y. H.; Maxson, R.; Hill, R. E.; Dale, T. C. Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during Foetal and Postnatal Mammary Gland Development. Development 1996, 122, 2729-2737.
80. Soda, H.; Raymond, E.; Sharma, S.; Lawrence, R.; Cerna, C.; Gomez, L.; Timony, G. A.; Von Hoff, D. D.; Izbicka, E. Antiproliferative Effects of Recombinant Human Bone Morphogenetic Protein-2 on Human Tumor Colony-Forming Units. Anticancer Drugs 1998, 9, 327-331.
81. Bentley, H.; Hamdy, F. C.; Hart, K. A.; Seid, J. M.; Williams, J. L.; Johnstone, D.; Russell, R. G. Expression of Bone Morphogenetic Proteins in Human Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia. Br. J. Cancer 1992, 66, 1159-1163.
82. Tateyama, S.; Uchida, K.; Hidaka, T.; Hirao, M.; Yamaguchi, R. Expression of Bone Morphogenetic Protein-6 (BMP-6) in Myoepithelial Cells in Canine Mammary Gland Tumors. Vet. Pathol. 2001, 38, 703-709.
83. Sharpe, W. S.; McDonald, J. R. Arch. Path. 1942, 312-325.
84. Piek, E.; Moustakas, A.; Kurisaki, A.; Heldin, C. H.; Dijke, P. TGF-(Beta) Type I Receptor/ALK-5 and Smad Proteins Mediate Epithelial to Mesenchymal Transdifferentiation in Nmumg Breast Epithelial Cells. J. Cell Sci. 1999, 112, 4557-4568.
85. Pouliot, F.; Labrie, C. Role of Smad1 and Smad4 Proteins in the Induction of P21 waf1,Cip1 during Bone Morphogenetic Protein-Induced Growth Arrest in Human Breast Cancer Cells. J. Endocrinol. 2002, 172, 187-198.
86. Ghosh-Choudhury, N.; Ghosh-Choudhury, G.; Celeste, A.; Ghosh, P. M.; Moyer, M.; Abboud, S. L.; Kreisberg, J. Bone Morphogenetic Protein-2 Induces Cyclin Kinase Inhibitor P21 and Hypophosphorylation of Retinoblastoma Protein in Estradiol-Treated MCF-7 Human Breast Cancer Cells. Biochim. Biophys. Acta 2000, 1497, 186-196.
87. Yamamoto, T.; Saatcioglu, F.; Matsuda, T. Cross-Talk between Bone Morphogenic Proteins and Estrogen Receptor Signaling. Endocrinology 2002, 143, 2635-2642.
88. Monroe, D. G.; Jin, D. F.; Sanders, M. M. Estrogen Opposes the Apoptotic Effects of Bone Morphogenetic Protein 7 on Tissue Remodeling. Mol. Cell. Biol. 2000, 20, 4626-4634.
89. Wijngaard, A.; Mulder, W. R.; Dijkema, R.; Boersma, C. J.; Mosselman, S. ; Zoelen, E. J. van; Olijve, W. Antiestrogens Specifically Up-Regulate Bone Morphogenetic Protein-4 Promoter Activity in Human Osteoblastic Cells, Mol. Endocrinol. 2000, 14, 623-633.
90. Ghosh-Choudhury, N.; Woodruff, K.; Qi, W.; Celeste, A.; Abboud, S. L.; Ghosh Choudhury, G. Bone Morphogenetic Protein-2 Blocks MDA MB 231 Human Breast Cancer Cell Proliferation by Inhibiting Cyclin-Dependent Kinase-Mediated Retinoblastoma Protein Phosphorylation. Biochem. Biophys. Res. Commun. 2002, 272, 705-711.
91. Teixeira, J.; Maheswaran, S.; Donahoe, P. K. Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications. Endocr. Rev. 2001, 22, 657-674.
92. Gouedard, L.; Chen, Y. G.; Thevenet, L.; Racine, C.; Borie, S.; Lamarre, I.; Josso, N.; Massague, J.; di Clemente, N. Engagement of Bone Morphogenetic Protein Type IB Receptor and Smad1 Signaling by Anti-Mullerian Hormone and Its Type II Receptor. J. Biol. Chem. 2000, 275, 27973-27978.
93. Jamin, S. P.; Arango, N. A.; Mishina, Y.; Hanks, M. C.; Behringer, R. R. Requirement of Bmprla for Mullerian Duct Regression during Male Sexual Development. Nat. Genet. 2002, 32, 408-410.
94. Jamin, S. P.; Arango, N. A.; Mishina, Y.; Behringer, R. R. Genetic Studies of MIS Signalling in Sexual Development. Novartis Found Symp. 2002, 244, 157-164.
95. Visser, J. A.; Olaso, R.; Verhoef-Post, M.; Kramer, P.; Themmen, A. P.; Ingraham, H. A. The Serine/Threonine Transmembrane Receptor ALK2 Mediates Mullerian Inhibiting Substance Signaling. Mol. Endocrinol. 2001, 15, 936-945.
96. Clarke, T. R.; Hoshiya, Y.; Yi, S. E.; Liu, X.; Lyons, K. M.; Donahoe, P. K. Mullerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces SMAD6 Expression. Mol. Endocrinol. 2001, 15, 946-959.
97. Segev, D. L.; Hoshiya, Y.; Stephen, A. E.; Hoshiya, M.; Tran, T. T.; MacLaughlin, D. T.; Donahoe, P. K.; Maheswaran, S. Mullerian Inhibiting Substance Regulates Nfkappab Signaling and Growth of Mammary Epithelial Cells In Vivo. J. Biol. Chem. 2001, 276, 26799-26806.
98. Shinkai, Y.; Rathbun, G.; Lam, K. P.; Oltz, E. M.; Stewart, V.; Mendelsohn, M.; Charron, J.; Datta, M.; Young, F.; Stall, A. M. RAG-2-Deficient Mice Lack Mature Lymphocytes Owing to Inability to Initiate V(D)J Rearrangement. Cell 1992, 68, 855-867.
99. Eickelberg, O.; Centrella, M.; Reiss, M.; Kashgarian, M.; Wells, R. G. Betaglycan Inhibits TGF-Beta Signaling by Preventing Type I-Type II Receptor Complex Formation. Glycosaminoglycan Modifications Alter Betaglycan Function. J. Biol. Chem. 2002, 277, 823-829.
100. Phillips, D. J. Regulation of Activin's Access to the Cell: Why Is Mother Nature Such a Control Freak. Bioessays 2000, 22, 689-696.
101. Lopez-Casillas, F.; Cheifetz, S.; Doody, J.; Andres, J. L.; Lane, W. S.; Massague, J. Structure and Expression of the Membrane Proteoglycan Betaglycan, A Component of the TGF-Beta Receptor System. Cell 1991, 67, 785-795.
102. Andres, J. L.; Stanley, K.; Cheifetz, S.; Massague, J. Membrane-Anchored and Soluble Forms of Betaglycan, A Polymorphic Proteoglycan That Binds Transforming Growth Factor-Beta. J. Cell Biol. 1989, 109, 3137-3145.
103. Vilchis-Landeros, M. M.; Montiel, J. L.; Mendoza, V.; Mendoza-Hernandez, G.; Lopez-Casillas, F. Recombinant Soluble Betaglycan Is a Potent and Isoform-Selective Transforming Growth Factor-Beta Neutralizing Agent. Biochem. J. 2001, 355, 215-222.
104. Esparza-Lopez, J.; Montiel, J. L.; Vilchis-Landeros, M. M.; Okadome, T.; Miyazono, K.; Lopez-Casillas, F. Ligand Binding and Functional Properties of Betaglycan, A Co-Receptor of the Transforming Growth Factor-Beta Superfamily. Specialized Binding Regions for Transforming Growth Factor-Beta and Inhibin A. J. Biol. Chem. 2001, 276, 14588-14596.
105. Sun, L.; Chen, C. Expression of Transforming Growth Factor Beta Type III Receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells. J. Biol. Chem. 1997, 272, 25367-25372.
106. Lyons, R. M.; Moses, H. L. Transforming Growth Factors and the Regulation of Cell Proliferation. Eur. J. Biochem. 1990, 187, 467-473.
107. Reiss, M. TGF-beta and cancer. Microbes Infect. 1999, 1, 1327-1347.
108. Arrick, B. A.; Korc, M.; Derynck, R. Differential Regulation of Expression of Three Transforming Growth Factor Beta Species in Human Breast Cancer Cell Lines by Estradiol. Cancer Res. 1990, 50, 299-303.
109. Arteaga, C. L.; Hurd, S. D.; Winnier, A. R.; Johnson, M. D.; Fendly, B. M.; Forbes, J. T. Anti-Transforming Growth Factor (TGF)-Beta Antibodies Inhibit Breast Cancer Cell Tumorigenicity and Increase Mouse Spleen Natural Killer Cell Activity. Implications for a Possible Role of Tumor Cell/Host TGF-Beta Interactions in Human Breast Cancer Progression. J. Clin. Invest. 1993, 92, 2569-2576.
110. Bandyopadhyay, A.; Zhu, Y.; Cibull, M. L.; Bao, L.; Chen, C.; Sun, L. A Soluble Transforming Growth Factor Beta Type III Receptor Suppresses Tumorigenicity and Metastasis of Human Breast Cancer MDA-MB-231 Cells. Cancer Res. 1999, 59, 5041-5046.
111. Bandyopadhyay, A.; Zhu, Y.; Malik, S. N.; Kreisberg, J.; Brattain, M. G. ; Sprague, E. A.; Luo, J.; Lopez-Casillas, F.; Sun, L. Z. Extracellular Domain of TGFbeta Type III Receptor Inhibits Angiogenesis and Tumor Growth in Human Cancer Cells. Oncogene 2002, 21, 3541-3551.
112. Lei, X.; Bandyopadhyay, A.; Le, T.; Sun, L. Autocrine TGFbeta Supports Growth and Survival of Human Breast Cancer MDA-MB-231 Cells. Oncogene 2002, 21, 7514-7523.
113. Bandyopadhyay, A.; Lopez-Casillas, F.; Malik, S. N.; Montiel, J. L.; Mendoza, V.; Yang, J.; Sun, L. Z. Antitumor Activity of a Recombinant Soluble Betaglycan in Human Breast Cancer Xenograft. Cancer Res. 2002, 62, 4690-4695.
114. Wiater, E.; Vale, W. Inhibin Is an Antagonist of Bone Morphogenetic Protein Signaling. J. Biol. Chem. 2003, 278, 7934-7941.
115. Burrows, F. J.; Derbyshire, E. J.; Tazzari, P. L.; Amlot, P.; Gazdar, A. F.; King, S. W.; Letarte, M.; Vitetta, E. S.; Thorpe, P. E. Up-Regulation of Endoglin on Vascular Endothelial Cells in Human Solid Tumors: Implications for Diagnosis and Therapy. Clin Cancer Res. 1995, 1, 1623-1634.
116. Seon, B. K.; Matsuno, F.; Haruta, Y.; Kondo, M.; Barcos, M. Long-Lasting Complete Inhibition of Human Solid Tumors in SCID Mice by Targeting Endothelial Cells of Tumor Vasculature with Antihuman Endoglin Immunotoxin. Clin. Cancer. Res. 1997, 3, 1031-1044.
117. Ohta, M.; Tokuda, Y.; Kuge, S.; Okumura, A.; Tanaka, M.; Kubota, M.; Tajima, T.; Akatsuka, A.; Osamura, R. Y.; Tamaoki, N.; Mitomi, T. A Case of Angiosarcoma of the Breast. Jpn. J. Clin. Oncol. 1997, 27, 91-94.
118. Bodey, B.; Bodey Jr, B.; Siegel, S. E.; Kaiser, H. E. Over-Expression of Endoglin (CD105): A Marker of Breast Carcinoma-Induced Neo-Vascularization. Anticancer Res. 1998, 18, 3621-3628.
119. Fonsatti, E.; Jekunen, A. P.; Kairemo, K. J.; Coral, S.; Snellman, M.; Nicotra, M. R.; Natali, P. G.; Altomonte, M.; Maio, M. Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model. Clin. Cancer Res. 2000, 6, 2037-2043.
120. Kumar, S.; Ghellal, A.; Li, C.; Byrne, G.; Haboubi, N.; Wang, J. M.; Bundred, N. Breast Carcinoma: Vascular Density Determined Using CD 105 Antibody Correlates with Tumor Prognosis. Cancer Res. 1999, 59, 856-861.
121. Seon, B. K.; Takahashi, N.; Haba, A.; Matsuno, F.; Haruta, Y.; She, X. W.; Harada, N.; Tsai, H. Angiogenesis and Metastasis Marker of Human Tumors. Rinsho Byori 2001, 49, 1005-1013.
122. Takahashi, N.; Kawanishi-Tabata, R.; Haba, A.; Tabata, M.; Haruta, Y.; Tsai, H.; Seon, B. K. Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and Suppressive Effect of Chemotherapy on the Serum Endoglin. Clin. Cancer Res. 2001, 7, 524-532.
123. Li, C. G.; Wilson, P. B.; Bernabeu, C.; Raab, U.; Wang, J. M.; Kumar, S. Immunodetection and Characterisation of Soluble CD105-Tgfbeta Complexes. J. Immunol. Methods 1998, 218, 85-93.
124. Li, C.; Wang, J.; Wilson, P. B.; Kumar, P.; Levine, E.; Hunter, R. D.; Kumar, S. Role of Transforming Growth Factor Beta3 in Lymphatic Metastasis in Breast Cancer. Int. J. Cancer 1998, 79, 455-459.
125. Matsuno, F.; Haruta, Y.; Kondo, M.; Tsai, H.; Barcos, M.; Seon, B. K. Induction of Lasting Complete Regression of Preformed Distinct Solid Tumors by Targeting the Tumor Vasculature Using Two New Anti-Endoglin Monoclonal Antibodies. Clin. Cancer. Res. 1999, 5, 371-382.
126. Tabata, M.; Kondo, M.; Haruta, Y.; Seon, B. K. Antiangiogenic Radioimmunotherapy of Human Solid Tumors in SCID Mice Using (125)I-Labeled Anti-Endoglin Monoclonal Antibodies. Int. J. Cancer 1999, 82, 737-742.
127. Li, C.; Wilson, P. B.; Levine, E.; Barber, J.; Stewart, A. L.; Kumar, S. TGF-Betal Levels in Pre-Treatment Plasma Identify Breast Cancer Patients at Risk of Developing Post-Radiotherapy Fibrosis. Int. J. Cancer 1999, 84, 155-159.
128. Luisi, S.; Calonaci, G.; Florio, P.; Lombardi, I.; Felice, C. De; Bagnoli, F.; Petraglia, F. Identification of Activin A and Follistatin in Human Milk. Growth Factors 2002, 20, 147-150.
129. Cipriano, S. C.; Chen, L.; Kumar, T. R.; Matzuk, M. M. Follistatin is a Modulator of Gonadal Tumor Progression and the Activin-Induced Wasting Syndrome in Inhibin-Deficient Mice. Endocrinology 2000, 141, 2319-2327.
130. Meehan, K. L.; Holland, J. W.; Dawkins, H. J. Proteomic Analysis of Normal and Malignant Prostate Tissue to Identify Novel Proteins Lost in Cancer. Prostate 2002, 50, 54-63.
131. Yuen, M. F.; Norris, S.; Evans, L. W.; Langley, P. G.; Hughes, R. D. Transforming Growth Factor-Beta 1, Activin and Follistatin in Patients with Hepatocellular Carcinoma and Patients with Alcoholic Cirrhosis. Scand. J. Gastroenterol. 2002, 37, 233-238.
132. Rossmanith, W.; Chabicovsky, M.; Grasl-Kraupp, B.; Peter, B.; Schausberger, E.; Schulte-Hermann, R. Follistatin Overexpression in Rodent Liver Tumors: A Possible Mechanism to Overcome Activin Growth Control. Mol. Carcinog. 2002, 35, 1-5.
133. Shimizu, H.; Julius, M. A.; Giarre, M.; Zheng, Z.; Brown, A. M.; Kitajewski, J. Transformation by Wnt Family Proteins Correlates with Regulation of Beta-Catenin, Cell Growth Differ. 1997, 8, 1349-1358.
134. Willert, J.; Epping, M.; Pollack, J. R.; Brown, P. O.; Nusse, R. A Transcriptional Response to Wnt Protein in Human Embryonic Carcinoma Cells. BMC Dev. Biol. 2002, 2, 8.
135. Pandis, N.; Teixeira, M. R.; Gerdes, A. M.; Limon, J.; Bardi, G.; Andersen, J. A.; ldvall, I.; Mandahl, N.; Mitelman, F.; Heim, S. Chromosome Abnormalities in Bilateral Breast Carcinomas. Cytogenetic Evaluation of the Clonal Origin of Multiple Primary Tumors. Cancer 1995, 76, 250-258.
136. Kallioniemi, A.; Kallioniemi, O. P.; Piper, J.; Tanner, M.; Stokke, T.; Chen, L.; Smith, H. S.; Pinkel, D.; Gray, J. W.; Waldman, F. M. Detection and Mapping of Amplified DNA Sequences in Breast Cancer by Comparative Genomic Hybridization. Proc. Natl. Acad Sci. USA 1994, 91, 2156-2160.
137. Hainsworth, P. J.; Raphael, K. L.; Stillwell, R. G.; Bennett, R. C.; Garson, O. M. Rearrangement of Chromosome 1p in Breast Cancer Correlates with Poor Prognostic Features. Br. J. Cancer 1992, 66, 131-135.
138. Dutrillaux, B.; Gerbault-Seureau, M.; Zafrani, B. Characterization of Chromosomal Anomalies in Human Breast Cancer. A Comparison of 30 Paradiploid Cases with Few Chromosome Changes. Cancer Genet. Cytogenet. 1990, 49, 203-217.
139. Bieche, I.; Khodja, A.; Lidereau, R. Deletion Mapping of Chromosomal Region 1p32-Pter in Primary Breast Cancer. Genes Chromosomes Cancer 1999, 24, 255-263.
140. Asmann, Y. W.; Kosari, F.; Wang, K.; Cheville, J. C.; Vasmatzis, G. Identification of Differentially Expressed Genes in Normal and Malignant Prostate by Electronic Profiling of Expressed Sequence Tags. Cancer Res. 2002, 62, 3308-3314.
141. Chen, B.; Athanasiou, M.; Gu, Q.; Blair, D. G. Drm/Gremlin Transcriptionally Activates P21(Cip1) Via a Novel Mechanism and Inhibits Neoplastic Transformation, Biochem. Biophys. Res. Commun. 2002, 295, 1135-1141.
142. Topol, L. Z.; Modi, W. S.; Koochekpour, S.; Blair, D. G. DRM/GREMLIN (CKTSF1B1) Maps to Human Chromosome 15 and Is Highly Expressed in Adult and Fetal Brain. Cytogenet. Cell Genet. 2000, 9, 79-84.
143. Yang, Y. A.; Tang, B.; Robinson, G.; Hennighausen, L.; Brodie, S. G.; Deng, C. X.; Wakefield, L. M. Smad3 in the Mammary Epithelium Has a Nonredundant Role in the Induction of Apoptosis, But Not in the Regulation of Proliferation or Differentiation by Transforming Growth Factor-Beta. Cell Growth Differ. 2002, 13, 123-130.
144. Weinstein, M.; Yang, X.; Deng, C. Functions of Mammalian Smad Genes as Revealed by Targeted Gene Disruption in Mice. Cytokine Growth Factor Rev. 2000, 11, 49-58.
145. Yang, X.; Letterio, J. J.; Lechleider, R. J.; Chen, L.; Hayman, R.; Gu, H.; Roberts, A. B.; Deng, C. Targeted Disruption of SMAD3 results in Impaired Mucosal Immunity and Diminished T Cell Responsiveness to TGF-Beta. Embo J. 1999, 18, 1280-1291.
146. Liu, X.; Yue, J.; Frey, R. S.; Zhu, Q.; Mulder, K. M. Transforming Growth Factor Beta Signaling through Smad1 in Human Breast Cancer Cells. Cancer Res. 1998, 58, 4752-4757.
147. Xie, W.; Mertens, J. C.; Reiss, D. J.; Rimm, D. L.; Camp, R. L.; Haffty, B. G.; Reiss, M. Alterations of Smad Signaling in Human Breast Carcinoma Are Associated with Poor Outcome: A Tissue Microarray Study. Cancer Res. 2002, 62, 497-505.
148. Pouliot, F.; Labrie, C. Expression Profile of Agonistic Smads in Human Breast Cancer Cells: Absence of Regulation by Estrogens. Int. J. Cancer 1999, 81, 98-103.
149. Gobbi, H.; Dupont, W. D.; Simpson, J. F.; Plummer, Jr., W. D.; Schuyler, P. A.; Olson, S. J.; Arteaga, C. L.; Page, D. L. Transforming Growth Factor-Beta and Breast Cancer Risk in Women with Mammary Epithelial Hyperplasia. J. Natl. Cancer Inst. 1999, 91, 2096-2101.
150. Gobbi, H.; Arteaga, C. L.; Jensen, R. A.; Simpson, J. F.; Dupont, W. D.; Olson, S. J.; Schuyler, P. A.; Plummer, Jr., W. D.; Page, D. L. Loss of Expression of Transforming Growth Factor Beta Type II Receptor Correlates with High Tumour Grade in Human Breast In-Situ and Invasive Carcinomas. Histopathology 2000, 36, 168-177.
151. Xie, W.; Rimm, D. L.; Lin, Y.; Shih, W. J.; Reiss, M. Loss of Smad Signaling is Associated with Poor Outcome in Human Colorectal Cancer. The Cancer Journal (Submitted).
152. Xie, W.; Rimm, D. L.; Reiss, M. Loss of Smad2 Activation Correlates with Poor Outcome in Human Colon Cancer-A Tissue Microarray Analysis. Proc. Am. Assoc. Cancer Res. 2001, 821.
153. Guise, T. A.; Yin, J. J.; Taylor, S. D.; Kumagai, Y.; Dallas, M.; Boyce, B. F.; Yoneda, T.; Mundy, G. R. Evidence for a Causal Role of Parathyroid Hormone-Related Protein in the Pathogenesis of Human Breast Cancer-Mediated Osteolysis. J. Clin. Invest. 1996, 98, 1544-1549.
154. Kakonen, S. M.; Selander, K. S.; Chirgwin, J. M.; Yin, J. J.; Burns, S.; Rankin, W. A.; Grubbs, B. G.; Dallas, M.; Cui, Y.; Guise, T. A. Transforming Growth Factor-Beta Stimulates Parathyroid Hormone-Related Protein and Osteolytic Metastases Via Smad and Mitogen-Activated Protein Kinase Signaling Pathways. J. Biol. Chem. 2002, 277, 24571-24578.
155. Lindemann, R. K.; Ballschmieter, P.; Nordheim, A.; Dittmer, J. Transforming Growth Factor Beta Regulates Parathyroid Hormone-Related Protein Expression in MDA-MB-231 Breast Cancer Cells through a Novel Smad/Ets Synergism. J. Biol. Chem. 2001, 276, 46661-46670.